Trust your gut: The Tipline for 20 November 2019
While Jonathan Baker, author of The Antitrust Paradigm, is calling on antitrust authorities to focus enforcement on harms to future products and innovation, one technology enforcer at the Federal Trade Commission is playing a little defence. Patricia Galvan pointed to the FTC’s work in the pharmaceuticals sector as an example of how the agency “consistently brings cases” when an acquisition of a competitor with a product in development is viewed as problematic. And in New York, the Department of Justice and counsel to former currency trader Akshay Aiyer jammed a 12-day trial into a single day of closing arguments.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10